What is included in the instructions for Napavir Sodium/Salanka?

Lenapavir sodium/Sunlenca (Sunlenca) is an innovative long-acting antiHIV (AIDS) drug, specially used to treat adult patients infected with multidrug-resistant HIV-1. The drug is available in both tablet and injection forms, and both have been approved for marketing in China. Compared with traditional antiretroviral drugs, lenapavir sodium is unique in its long-acting effect and flexible dosing regimen, which allows patients to obtain more stable viral suppression while reducing the burden of daily medication. Currently, there is no generic version of this drug in China, and patients can only use the original drug.

1. Indications and treatment groups

Lenapavir sodium is mainly suitable for adultsHIV-1 infected patients. Such patients have usually been treated with multiple antiretroviral drugs, but the virus has not been effectively controlled, that is, multi-drug resistance has occurred. This drug is used in conjunction with other anti-HIV drugs to help inhibit viral replication and reduce HIV levels in the blood. It is particularly suitable for patients who have failed to respond to existing antiviral regimens, providing a new treatment option.

2. Dosage regimen and usage

Lenapavir sodium provides two main dosage regimens, and patients can choose the regimen that best suits them based on their doctor’s evaluation. The first regimen is to complete the initial dose through two injections combined with two oral tablets on the 1st day of treatment, and then take two oral tablets on the 2nd day, followed by two injections every 6 months from the date of the last injection to maintain blood concentration and inhibitory effect. The second plan is more phased, with two tablets taken orally daily on days 1 and 2, one tablet taken orally on day 8, and two injections received on day 15. Subsequently, the treatment effect is maintained at an injection interval of every 6 months. These protocols ensure that the drug reaches a stable concentration in the body while reducing the risk of viral mutation and drug resistance.

3. Treatment management and precautions

During the treatment process, patients must strictly follow the plan formulated by the doctor for injections and medication. Missed injections may cause the HIV-1 virus to mutate, leading to drug resistance and making subsequent treatment more difficult. If lenapavir sodium or other antiretroviral drugs are discontinued for any reason, the attending physician should be informed immediately and alternative options should be discussed to ensure that the virus continues to be effectively suppressed. Continuous monitoring of viral load and immune function indicators is an important step in ensuring efficacy and preventing drug resistance.

4. Clinical value and prospects

The launch of napavir sodium marks the beginning of anti-HIV treatment has entered a new stage of long-term effectiveness and convenience. Its long-acting injection form is particularly suitable for patients with poor compliance or who have failed long-term multi-drug therapy, while the existence of tablets also provides flexibility for individualized treatment. Long-acting dosing not only helps improve quality of life but may also reduce the risk of viral recurrence due to treatment interruption. With the continuous advancement of HIV treatment around the world, lenapavir sodium is expected to become an important treatment option for patients with multidrug resistance and promote the development of long-term HIV management in a more refined and convenient direction.

In short, lenapavir sodium provides new hope for patients with multidrug-resistantHIV through its unique long-acting mechanism and diverse administration methods. Whether it is a tablet or an injection, patients are required to strictly follow the doctor's instructions to ensure efficacy and prevent the occurrence of drug resistance.

Reference materials:https://www.drugs.com/sunlenca.html